Accelerate Diagnostics Inc Année d'introduction en bourse
Quel est le Année d'introduction en bourse de Accelerate Diagnostics Inc?
Le Année d'introduction en bourse de Accelerate Diagnostics Inc est 1996
Quelle est la définition de Année d'introduction en bourse?
Le premier appel public à l'épargne est un type d'offre publique dans lequel les actions d'une entreprise sont généralement vendues à des investisseurs institutionnels qui, pour leur part, vendent au grand public, pour la première fois, sur une bourse de valeurs.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Année d'introduction en bourse des entreprises dans Health Care secteur sur NASDAQ par rapport à Accelerate Diagnostics Inc
Que fait Accelerate Diagnostics Inc?
accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Entreprises avec année d'introduction en bourse similaire à Accelerate Diagnostics Inc
- Shaw Communications a Année d'introduction en bourse de 1995
- Husky a Année d'introduction en bourse de 1995
- Transcontinental , Cl B Mv a Année d'introduction en bourse de 1995
- Mountain Inc a Année d'introduction en bourse de 1995
- Brookfield Asset Management a Année d'introduction en bourse de 1995
- ShawCor a Année d'introduction en bourse de 1995
- Accelerate Diagnostics Inc a Année d'introduction en bourse de 1996
- BXP a Année d'introduction en bourse de 1997
- Faro Technologies a Année d'introduction en bourse de 1997
- Silgan a Année d'introduction en bourse de 1997
- Warrior Gold a Année d'introduction en bourse de 1997
- Ryanair Plc a Année d'introduction en bourse de 1997
- SIGA Technologies Inc a Année d'introduction en bourse de 1997